like dulaglutide and exenatide XR, were developed to act as a long-acting GLP-1 analog, replacing the previous subcutaneous injections once daily with once weekly administration, potentially improving patient adherence and convenience (Lau et al., 2015)
The 20.7% figure comes from the STEP-UP trial of 1,742 adults living with obesity, published in NEJM in 2025
GLP-1 receptors are expressed in mesolimbic reward brain regions, including the nucleus accumbens
CJC-1295 is generally well-tolerated because it stimulates your bodys natural processes rather than introducing foreign hormones
Interestingly, they also reported that a subgroup had enrichment in E
Semaglutide (Wegovy) recently became the first GLP-1 approved by the FDA to treat adults with MASH with moderate-to-advanced fibrosis, based on the phase 3 ESSENCE trial